Tele: 561.316.3330
Breaking Medical Device News

Monday, October 18, 2021
HomeClearMind Biomedical Inc.Axonpen Neuroendoscope Receives 510K Clearance: 1st Post Market Human Trial Commences

Axonpen Neuroendoscope Receives 510K Clearance: 1st Post Market Human Trial Commences

January 11, 2021

Axonpen neuroendoscope has received 510K clearance reports ClearMind Biomedical, Inc. Requiring only a narrow channel of 6.5mm through the skull for insertion into the brain, the steerable Axonpen neuroendoscope combines excellent tissue visualization, suction, and irrigation functions.

It has a working channel for use with accessory surgical devices. The Axonpen System is the first neuroendoscope to integrate all these capabilities into one, simple to use, minimally invasive operating platform.

The Axonpen neuroendoscope system supports a clinical shift in the minimally invasive removal of unwanted intracranial fluid and tissue, as commonly manifested in cases of intracerebral hemorrhage (ICH) and subdural hematomas.

One Doctor, One Hour” was the objective driving the ClearMind founders to create the Axonpen neuroendoscope system. Meeting this objective allows a single surgeon to complete some critical surgeries in one hour, even at small-scale regional hospitals. More importantly, access to faster neurosurgical interventions after suffering a hemorrhagic stroke or other fluid producing injury has the potential to improve patient outcomes, including survival.

“Up until the introduction of the Axonpen System, there has been no other integrated neuroevacuation device on the market for minimally invasive neurosurgery,” explains Carrey Yang, ClearMind’s CEO. “Often, expensive and complex equipment is necessary to perform the surgery, requiring that patients be transferred to a large medical center, delaying the moment surgery can begin.”

Yang also pointed out examples where the Axonpen may provide benefit: “The most critical period in treating ICH is the first 24 hours, underscoring the importance of swift and effective emergency treatment.”  He went on to comment that apart from the speediness of treatment, the Axonpen’s low rebleeding risk is an equally important advantage.

The first post-market human trial of the Axonpen has commenced. The trial, which will consist of 30 subjects, is focused on procedural safety and generating the correlation between the use of the Axonpen System and functional independence measures. US human trials are planned for the 3rd quarter of 2021.

Medical Device News Magazine
Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Stay Connected


Don't Miss

Insulet Announces Board of Director Changes with Appointment of Luciana Borio, M.D. and Retirement of Sally W. Crawford

Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced...

Ganymed Robotics Awarded a €2.5M Grant from the EC through the EIC Accelerator Program

Ganymed Robotics is developing a radically new approach to surgical robotics by combining computer vision, a branch of artificial intelligence, and mechatronics.

Global Healthcare Exchange Announces Acquisition of Explorer Surgical

Explorer Surgical will operate as a wholly-owned subsidiary of GHX.

Arlington Scientific Broadens Product Portfolio and Further Expands its Product Offering Through the acquisition of Non-Mammalian Blocking Buffers

Arlington Scientific, Inc. (ASI) is pleased to announce that it has acquired the non-mammalian blocking buffer product line from Clark McDermith, former owner of...

Laborie Medical Technologies Acquires Pelvalon

Laborie was represented by Piper Sandler (financial advisor) and Simpson Thacher & Bartlett LLP (legal advisor). Pelvalon was represented by J.P. Morgan Securities LLC (financial advisor) and Dorsey & Whitney LLP (legal advisor).

Herculite Products, Inc. Promotes Two Employees to New Roles

Paul Flaherty Chief Strategy Officer and Marco Angelone is being promoted to the role of Chief Financial Officer.

Prof. Joseph Kvedar Added to the Sweetch Advisory Board Member

Prof. Josdeph Kvedar is the current chair of the board at the American Telemedicine Association (ATA), formerly VP of Connected Health at Mass-Gen Brigham, co-chair of the American Medical Association (AMA) Digital Medicine Payment Advisory Group, and author of The Internet of Healthy Things and The New Mobile Age.

Sid Bala Named President of HealthChampion

Sid Bala is the former president and chief executive officer of alligatortek, a custom software applications company that was acquired by HealthChampion in 2020 where he led them for 27 years after he founded the business

By using this website you agree to accept Medical Device News Magazine Privacy Policy